Product: Nodify XL2
-
Nodule Dilemma: Proteomic Biomarker Discordance with PET Results
-
Assessment of Integrated Classifier’s Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2 Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
-
Lung Nodule Integrated Classifier Biomarker: First Data with Real-World Clinical Use
-
First Look at the Distribution of Risk of Malignancy Pre and Post-Test Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study
-
Utilizing a Nodule Classifier for Management of Incidental Nodules: A Case Report
-
Early diagnosis pulmonary nodules: cancer diagnosis timing during CT surveillance in the PANOPTIC study
-
Early diagnosis of pulmonary nodules: biomarker performance in patients with solitary or multiple nodules in the PANOPTIC study
-
Early diagnosis of pulmonary nodules: biomarker performance in cancer subtypes found in the PANOPTIC study
-
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
-
Pulmonary Nodule Biomarker PANOPTIC study results at 1-year supported by 2-year results